Cerebrovaskularni poradna s.r.o.
- Address
- lock Available on a paid plan
Cardiovascular Diseases
The department investigates high‑risk atrial fibrillation patients who have experienced prior intracranial hemorrhage, aiming to reduce future stroke and systemic embolism. The study compares an oral anticoagulant with standard non‑anticoagulant therapy to determine safety and effectiveness.
- Evaluation of edoxaban versus non‑anticoagulant medical therapy
- Assessment of composite stroke and embolism risk reduction
- Safety monitoring in patients with previous brain bleed
This work is conducted at Cerebrovaskularni poradna s.r.o., contributing to improved cardiovascular care in the region.
Nervous System Diseases
Clinical trials focus on individuals with prolonged stereotypical seizures, testing a rapid‑acting formulation to quickly stop seizure activity. Researchers evaluate the ability to terminate seizures within 90 seconds and prevent recurrence for up to two hours. Long‑term tolerability of the investigational product is also examined in adolescents and adults.
- Rapid seizure termination within 90 seconds
- Prevention of seizure recurrence for two hours
- Safety assessment in patients aged 12 and older
The site’s expertise in neurological emergencies supports the development of faster, safer seizure therapies.
Respiratory Tract Diseases
Studies target moderate to severe obstructive sleep apnea in overweight or obese adults, evaluating a novel agent to improve breathing during sleep. The trial measures changes in the Apnea‑Hypopnea Index and compares outcomes with placebo while patients continue positive airway pressure therapy. The goal is to enhance treatment effectiveness and quality of life.
- Improvement in Apnea‑Hypopnea Index
- Comparison with placebo in sleep‑disordered breathing
- Assessment of weight‑related benefits
Conducted at Cerebrovaskularni poradna s.r.o., this research expands respiratory care options for patients with sleep‑related breathing disorders.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 3 by active trials.
- 1UCB Biopharma2active
lock +2 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1UCB Biopharma2trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 634 other sites in Czechia
Therapeutic Area Benchmark — Czechia
Select a therapeutic area to compare against other sites in Czechia.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Czechia
Market Share
Country: Czechia
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Cerebrovaskularni poradna s.r.o.
lock Showing 1 of 6 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active-Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation | Janssen Cilag International | Phase III | Not Recruiting | Aug 2023 | — |
IMP list
lock Showing 1 of 7 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Alprazolam | 2 | Unknown | 2022-07-21 | 2022-09-26 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.